Dr. Archana S. Nagaraja

Arcus Biosciences, Inc, USA

Senior Scientist

Email: [email protected]

Qualifications

2017 Ph.D., The University of Texas Health Science Center, USA

2010 M.Sc., Drexel University, USA

Publications (Selected)

1. Nagaraja, A.S., Rayaji, R., Patel, B., Singh, R., Chandrasekar, S., Guan, Y. and others. Sa1453 TNF INDUCES TNFR2 IN HUMAN INTESTINAL EPITHELIAL CELLS AND INHIBITION OF TNF WITH A SMALL-MOLECULE INHIBITOR SUPPRESSES IFN-γ PRODUCTION IN TH1 CELLS AND MAINTAINS INTESTINAL BARRIER INTEGRITY. Gastroenterology, 170(6):S-937-S-938, 2026.
2. Lin, N., Huang, T., Patel, C.J., Poole, E.M., Clish, C.B. and Armaiz-Pena, G.N. Plasma and ovarian metabolomic responses to chronic stress in female mice. Metabolomics, 21(4), 99, 2025.
3. Rodriguez-Aguayo, C., Bayraktar, E., Ivan, C., Aslan, B., Mai, J., He, G. and others. Corrigendum to “PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis”[EBioMedicine 40 (2019) 290-304]. EBioMedicine, 83, 2022.
4. Haria, D., Lee, J., Guagua, J., Nagaraja, A., Roskamp, K., Hwang, B.Y. and others. Targeting the CXCR3 pathway with a novel peptide drug candidate mobilizes the immune system to enhance anti-tumor immunity. Cancer Research, 82(12_Supplement), 6349, 2022.
5. Zeleznik, O.A., Huang, T., Patel, C.J., Poole, E.M., Clish, C.B., Armaiz-Pena, G.N. and others. Plasma and ovarian metabolomic responses to chronic stress in female mice. bioRxiv, 2022.
6. Lin, M., Nagaraja, A.S., Haria, D., Katlinskaya, Y., Ravichandar, D., Williams, P. and others. Abstract P260: Development and validation of a novel T-cell modulating, microbiome-based peptide for combination with immunotherapy. Molecular Cancer Therapeutics, 20(12_Supplement), P260, 2021.
7. Gonzalez-Junca, A., Liu, F.D., Nagaraja, A.S., Mullenix, A., Lee, C.T., Gordley, R.M. and others. SENTI-101, a preparation of mesenchymal stromal cells engineered to express IL12 and IL21, induces localized and durable antitumor immunity in preclinical models of peritoneal carcinomatosis. Molecular Cancer Therapeutics, 20(9):1508-1520, 2021.
8. Wagner, M.J., Lyons, Y.A., Siedel, J.H., Dood, R., Nagaraja, A.S., Haemmerle, M. and others. Combined VEGFR and MAPK pathway inhibition in angiosarcoma. Scientific Reports, 11(1), 9362, 2021.
9. Mangala, L.S., Wang, H., Jiang, D., Wu, S., Somasunderam, A., Volk, D.E. and others. Erratum: Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy (JCI Insight.(2016) 1: 17 (e87754). JCI Insight, 6(7), e149896, 2021.
10. Nagaraja, A.S., Dood, R.L., Armaiz-Pena, G., Kang, Y., Wu, S.Y., Allen, J.K. and others. Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens. JCI Insight, 6(7), e149895, 2021.
11. Moreno-Smith, M., Halder, J.B., Meltzer, P.S., Gonda, T.A., Mangala, L.S. and others. ATP11B mediates platinum resistance in ovarian cancer. The Journal of Clinical Investigation, 131(7), 2021.
12. Gonzalez, A., Liu, F.D., Nagaraja, A., Mullenix, A., Gordley, R.M. and others. SENTI-101, a novel genetically modified allogeneic cell product expressing IL12 and IL21, elicits a tumor-localized, robust, and multimodal immune response in preclinical models of peritoneal carcinomatosis. Cancer Research, 80(16_Supplement), 4246, 2020.
13. Junca, A.G., Lee, G., Nagaraja, A., Mullenix, A., Gordley, R., Frimannson, D. and others. SENTI-101, an allogeneic cell product, induces potent and durable anti-tumor immunity in pre-clinical models of peritoneal carcinomatosis. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 7, 2019.
14. Rodriguez-Aguayo, C., Bayraktar, E., Ivan, C., Aslan, B., Mai, J., He, G. and others. PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis. EBioMedicine, 40:290-304, 2019.
15. Hisamatsu, T., McGuire, M., Wu, S.Y., Rupaimoole, R., Pradeep, S., Bayraktar, E. and others. PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer. Molecular Cancer Therapeutics, 18(1):162-172, 2019.
16. Gharpure, K.M., Pradeep, S., Sans, M., Rupaimoole, R., Ivan, C., Wu, S.Y. and others. FABP4 as a key determinant of metastatic potential of ovarian cancer. Nature Communications, 9(1), 2923, 2018.
17. Allen, J.K., Armaiz-Pena, G.N., Nagaraja, A.S., Sadaoui, N.C., Ortiz, T., Dood, R. and others. Sustained adrenergic signaling promotes intratumoral innervation through BDNF induction. Cancer Research, 78(12):3233-3242, 2018.
18. Nagaraja, A.S., Dood, R.L., Armaiz-Pena, G., Kang, Y., Wu, S.Y., Allen, J.K. and others. Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens. JCI Insight, 3(11), e122389, 2018.
19. Gharpure, K.M., Lara, O.D., Wen, Y., Pradeep, S., LaFargue, C., Ivan, C. and others. ADH1B promotes mesothelial clearance and ovarian cancer infiltration. Oncotarget, 9(38):25115, 2018.
20. Huang, Y., Hu, W., Huang, J., Shen, F., Sun, Y., Ivan, C., Pradeep, S., Dood, R. and others. Inhibiting nuclear phospho-progesterone receptor enhances antitumor activity of onapristone in uterine cancer. Molecular Cancer Therapeutics, 17(2):464-473, 2018.

Personal Details

WoS Researcher ID: AAE-2205-2021

https://orcid.org/0000-0002-2851-9272

https://www.linkedin.com/in/archanasn/

https://scholar.google.com/citations?user=IQXUIb4AAAAJ&hl=en

https://www.sciencedirect.com/author/54397274400/archana-sidalaghatta-nagaraj